JPH0532371B2 - - Google Patents
Info
- Publication number
- JPH0532371B2 JPH0532371B2 JP58100315A JP10031583A JPH0532371B2 JP H0532371 B2 JPH0532371 B2 JP H0532371B2 JP 58100315 A JP58100315 A JP 58100315A JP 10031583 A JP10031583 A JP 10031583A JP H0532371 B2 JPH0532371 B2 JP H0532371B2
- Authority
- JP
- Japan
- Prior art keywords
- mps
- substance
- liver
- reaction
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000126 substance Substances 0.000 claims description 21
- 150000004676 glycans Chemical class 0.000 claims description 11
- 229920001282 polysaccharide Polymers 0.000 claims description 11
- 239000005017 polysaccharide Substances 0.000 claims description 11
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- FNEHAOQZWPHONV-UHFFFAOYSA-N 9h-carbazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 FNEHAOQZWPHONV-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- MMCPOSDMTGQNKG-UHFFFAOYSA-N anilinium chloride Chemical compound Cl.NC1=CC=CC=C1 MMCPOSDMTGQNKG-UHFFFAOYSA-N 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Description
【発明の詳細な説明】
本発明は、高分子多糖類物質MPS−80を有効
成分とする脂肪肝抑制剤に関するものである。
一般に、食品の構成成分の一つである多糖類
は、近年、多くの疫学調査の結果から、大腸が
ん、動脈硬化性疾患など多くの疾病予防に重要な
役割を果たしていることが明らかとなつてきた。
中でも、血中コレステロール上昇を抑制する作用
が多糖類に存在することが明らかになるにつれ、
動脈硬化性疾患の予防と治療の面から注目される
ようになつた。
本発明者らは、先に、各種乳酸菌から新規高分
子多糖類物質MPS−80（特開昭57−117503）を見
出すに至つたが、MPS−80が生理的に有用な高
分子多糖類であるところから、MPS−80が肝臓
の高脂肪化を抑制する効果を有するのではないか
との期待から鋭意研究したところ、MPS−80に
肝臓への脂質の蓄積を抑制する作用が存在するこ
とを知つた。
本発明は、この知見から完成されたもので、各
種乳酸菌培養液中に存在する高分子多糖類物質
MPS−80を有効成分とする脂肪肝抑制剤に関す
るものである。
本発明においては、MPS−80を経口投与剤と
して投与を続ければ、高脂肝症治療ならびに予防
に効果的である。投与量としてはMPS−80 0.1
〜30ｇ／Kg／日程度である。
次にMPS−80について説明する。
MPS−80はLactobacillus jugurtiNo.851、
FERM BP−66又は、Streptococcus
thermophilusNo.127、FERM BP−65によつて生
産される。
MPS−80の理化学的性質は次の通りである。
(1) 元素分析
Ｃ：42.2％
Ｈ：6.9％
Ｏ：50.4％
(2) 分子量
（） 限外過法による場合。
Sepharose2Bによる限外過を行なつた結
果を第１図に示した。
カラムサイズ2.5×40.5cm；フラクシヨン
５ｇ；試料2.5mg（１ml）を負荷；展開剤
0.05Mりん酸緩衝液（PH6.0）；の条件によ
り、本物質はほぼVoid Volume付近に分画
される。
（） 超遠心法による場合。
0.2Mりん酸緩衝液（PH7.3）に0.1％濃度で
溶解した試料について超遠心法（設定回転数
51200RPM）により沈降定数を求めたところ
7.98S（Ｓ：Svedberg単位）であつた。（沈降
は単一状態を示した。）
(3) 融点（分解点）
本物質は262℃付近で変色が始まり、263〜
264℃で黒変する。
(4) 比施光度
〔α〕18 D＝＋33.2（Ｃ＝0.5％）
(5) 紫外部吸収スペクトル
第２図に示す通りである。
(6) 赤外部吸収スペクトル
第３図に示す通りである。
(7) 溶剤に対する溶解性
水に可溶、メタノール、エタノール、アセト
ン、エーテルに不溶。
(8) 呈色反応
（） モーリツシユ反応 ＋
（） アンスロン反応 ＋
（） システイン−硫酸反応 ＋
（） アニリン−塩酸反応 −
（） カルバゾール−硫酸反応 −
（） エルソン−モリガン反応 −
（） ビユレツト反応 −
(9) 塩基性、酸性、中性の別
本物質の0.1％〜0.5％水溶液のPHは中性であ
る。
(10) 物質の色
本物質の凍結乾燥物は白色繊維状である。
(11) 構成糖の種類
５％SE−52（２ｍカラム）を使用し、GLCに
よる構成糖の種類を調べた。
条件：昇温150℃〜230℃（３℃／min）試料を
2N−H2SO4で沸とう水中４時間加水分解し、
炭酸バリウムで中和後過した。液につい
てアンバーライトIRA−410およびアンバー
ライトIR−120Bで脱塩後濃縮乾固し、TMS
化してGLCにかけた。その結果、本物質の
構成糖としてグルコース、ガラクトースが認
められた。
(12) 構成糖の組成比
試料を2N−H2SO4で沸とう水中４時間加水
分解し、炭酸バリウムで中和後過し、その
液について酵素法により構成糖の組成比を調べ
た。その結果グルコース：ガラクトース＝2.2
〜1.91であつた。
(13) C13−NMRスペクトル（D2O中、TMS基準）
（ppm）
第４図に結果を示した。
(14) 酵素による分解性
0.05M酢酸緩衝液に溶解した本物質について
各種酵素を作用させた。酵素による分解性はソ
モギー・ネルソン法による還元糖量の増加で判
定した。
使用した酵素と反応条件
ａ α−Amylase（ベーリンガー社）PH5.9、
37℃、４時間
ｂ β−Amylase（ 〃 ）PH4.8、
30℃、４時間
ｃ β−Galactosidase（ 〃 ）PH
4.8、
30℃、４時間
ｄ Amyloglucosidase（ 〃 ）PH
4.8、
30℃、４時間
ｅ α−Galactosidase（ 〃 ）PH
4.8、
30℃、４時間
上記条件下ではａ〜ｅすべてにおいて、還元
糖量の増加は全く認められなかつた。
(15) LD50
ddY5 ｗ♀マウス（平均体重21.3ｇ、１群７
匹）を用い、生理食塩水に溶解した試料を各種
投与量で腹腔内に１回投与して10日間観察し
LD50を求めた。その結果LD50は200mg／Kg体重
以上であつた。
次に本発明の製造例、実施例を示す。
製造例
ホエー培地（10％ｗ／ｖホエー粉＋0.5％ｗ／
ｖビール酵母エキス）10にLactobacillus
JugurtiNo.851、FERM BP−66を接種し、37℃で
24時間静置培養し、培養終了後、遠心分離
（10000rpm、15min）にて培養上澄液9.2を得
る。この上澄液に99.5％エチルアルコールを最終
濃度として35％（ｖ／ｖ）となるように添加す
る。本操作により沈澱物質が認められるようにな
り、この沈澱物質を遠心分離（10000rpm、
5min）し、沈澱物質1.2ｇを得る。
この沈澱物質にイオン交換水を加え溶解後、不
溶静物質を遠心分離（10000rpm、15min）にて
除去する。本操作を計３回繰り返すことにより
800mgの粗精製物が得られる。
ここに得られた粗精製物を0.05Mりん酸緩衝液
（PH6.0）に溶解し、同緩衝液で十分に緩衝化した
ジエチルアミノエチルセルロース（DEAE−セル
ロース）を充填したカラムに負荷する。同緩衝液
を流し、DEAE−セルロースに非吸着性物質を含
む通過液を採取する。非吸着性物質を含む溶液を
凍結乾燥した後、イオン交換水に溶解し、イオン
交換水に対して10℃で４日間、透析チユーブにて
透析を行なう。透析終了後、透析内液を凍結乾燥
し、高分子多糖類物質MPS−80の凍結乾燥標品
500mgを得る。
実施例
製造例で得られた培養液をそのままアルコール
沈澱させて得られた粗物質（MPS−80を３％
含有する）を市販のラツト、マウス繁殖用飼料に
10％添加混合した。これを飼料とする。
対照として、ホエー蛋白質を同じ市販のラツ
ト、マウス繁殖用飼料に10％添加混合した。これ
を飼料とする。各群の飼料の蛋白質量、エネル
ギー等の内容は同じになるようにした。動物とし
て、離乳直後の体重40〜50ｇの高血圧自然発症ラ
ツト（SHR）雄を用いた。
実験区は、SHRを30匹、飼料にて飼育し
た。実験区は、同じくSHRを30匹飼料にて
飼育した。両実験区共に３週間毎に10匹ずつ脱血
により屠殺し、肝臓を摘出した。肝臓中の脂質含
量を測定した。実験結果を表１、第５図及び第６
図に示した。
体重増加は、両実験区において差はなかつた。
肝臓中の脂質合量は実験区において６〜９週齢
で有意に低かつた。GOT、GPTは両群で差はな
かつた。
したがつて、高分子多糖類物質MPS−80を含
んだ飼料を与えられたラツトの方が、肝臓への脂
質の蓄積が抑えられることが分かる。
【表】DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a fatty liver inhibitor containing a high molecular weight polysaccharide substance MPS-80 as an active ingredient. In general, polysaccharides, which are one of the constituents of food, have recently been shown to play an important role in preventing many diseases such as colorectal cancer and arteriosclerotic diseases, based on the results of many epidemiological studies. It's here.
In particular, as it became clear that polysaccharides have the ability to suppress the rise in blood cholesterol,
It has started to attract attention from the perspective of prevention and treatment of arteriosclerotic diseases. The present inventors previously discovered a novel polymeric polysaccharide substance MPS-80 (Japanese Patent Application Laid-Open No. 117503/1983) from various lactic acid bacteria. Based on the expectation that MPS-80 might have the effect of suppressing high fat content in the liver, we conducted intensive research and discovered that MPS-80 has the effect of suppressing lipid accumulation in the liver. I knew. The present invention was completed based on this knowledge, and is based on the polymer polysaccharide substances present in various lactic acid bacteria culture solutions.
This invention relates to a fatty liver inhibitor containing MPS-80 as an active ingredient. In the present invention, if MPS-80 is continuously administered as an oral drug, it is effective in treating and preventing hyperlipidemia. The dosage is MPS−80 0.1
~30g/Kg/day. Next, the MPS-80 will be explained. MPS−80 is Lactobacillus jugurti No.851,
FERM BP−66 or Streptococcus
thermophilus No. 127, produced by FERM BP-65. The physical and chemical properties of MPS-80 are as follows. (1) Elemental analysis C: 42.2% H: 6.9% O: 50.4% (2) Molecular weight () When using ultrafiltration method. The results of ultraviolet analysis using Sepharose 2B are shown in Figure 1. Column size 2.5 x 40.5 cm; fraction 5 g; sample 2.5 mg (1 ml) loaded; developer
Under the conditions of 0.05M phosphate buffer (PH6.0), this substance is fractionated almost to the void volume. () When using ultracentrifugation. A sample dissolved in 0.2M phosphate buffer (PH7.3) at a concentration of 0.1% was subjected to ultracentrifugation (set rotation speed).
51200RPM) to determine the sedimentation constant.
It was 7.98S (S: Svedberg unit). (Sedimentation showed a single state.) (3) Melting point (decomposition point) This substance begins to change color at around 262°C, and from 263°C to
It turns black at 264℃. (4) Specific power [α] 18 D = +33.2 (C = 0.5%) (5) Ultraviolet absorption spectrum As shown in Figure 2. (6) Infrared absorption spectrum As shown in Figure 3. (7) Solubility in solvents Soluble in water, insoluble in methanol, ethanol, acetone, and ether. (8) Color reaction () Moritsch reaction + () Anthrone reaction + () Cysteine-sulfuric acid reaction + () Aniline-hydrochloric acid reaction − () Carbazole-sulfuric acid reaction − () Elson-Morrigan reaction − () Buillet reaction − ( 9) Basic, acidic, and neutral The pH of a 0.1% to 0.5% aqueous solution of this substance is neutral. (10) Color of substance The lyophilized product of this substance is white fibrous. (11) Types of constituent sugars The types of constituent sugars were investigated by GLC using 5% SE-52 (2m column). Conditions: Temperature increase from 150℃ to 230℃ (3℃/min)
Hydrolyzed in boiling water with 2N−H 2 SO 4 for 4 hours,
It was neutralized with barium carbonate and filtered. About the solution, desalt with Amberlite IRA-410 and Amberlite IR-120B, concentrate to dryness, and TMS.
and applied it to GLC. As a result, glucose and galactose were recognized as constituent sugars of this substance. (12) Composition ratio of constituent sugars A sample was hydrolyzed in boiling water with 2N-H 2 SO 4 for 4 hours, neutralized with barium carbonate, filtered, and the composition ratio of constituent sugars was investigated using the enzyme method. As a result glucose: galactose = 2.2
It was ~1.91. (13) C 13 −NMR spectrum (in D 2 O, TMS standard)
(ppm) The results are shown in Figure 4. (14) Degradability by enzymes Various enzymes were allowed to act on this substance dissolved in 0.05M acetate buffer. Enzymatic degradability was determined by the increase in reducing sugar amount using the Somogyi-Nelson method. Enzyme used and reaction conditions a α-Amylase (Boehringer) PH5.9, 37℃, 4 hours b β-Amylase (〃) PH4.8, 30℃, 4 hours c β-Galactosidase (〃) PH
4.8, 30℃, 4 hours d Amyloglucosidase (〃)PH
4.8, 30℃, 4 hourse α-Galactosidase (〃)PH
4.8, 30°C, 4 hours Under the above conditions, no increase in reducing sugar amount was observed in all a to e. (15) LD 50 ddY5 w♀ mice (average weight 21.3g, 7 in 1 group)
Samples dissolved in physiological saline were administered intraperitoneally once at various doses to 100 mice, and observed for 10 days.
Asked for LD50 . As a result, LD 50 was more than 200 mg/Kg body weight. Next, production examples and examples of the present invention will be shown. Production example Whey medium (10% w/v whey powder + 0.5% w/
v beer yeast extract) Lactobacillus in 10
Jugurti No. 851, inoculated with FERM BP−66 and incubated at 37℃
Static culture is carried out for 24 hours, and after completion of culture, culture supernatant 9.2 is obtained by centrifugation (10000 rpm, 15 min). To this supernatant, 99.5% ethyl alcohol is added to a final concentration of 35% (v/v). As a result of this operation, precipitated substances can be observed, and these precipitated substances are centrifuged (10,000 rpm,
5 min) to obtain 1.2 g of precipitated material. After dissolving the precipitated material by adding ion-exchanged water, undissolved material is removed by centrifugation (10,000 rpm, 15 min). By repeating this operation three times in total
800 mg of crude product is obtained. The crude product obtained here is dissolved in 0.05M phosphate buffer (PH6.0) and loaded onto a column packed with diethylaminoethylcellulose (DEAE-cellulose) sufficiently buffered with the same buffer. The same buffer solution is passed through, and the flow-through solution containing substances not adsorbed to DEAE-cellulose is collected. After the solution containing the non-adsorbable substance is freeze-dried, it is dissolved in ion-exchanged water and dialyzed against ion-exchanged water at 10° C. for 4 days in a dialysis tube. After dialysis, the dialysis fluid is freeze-dried and a freeze-dried specimen of the polymeric polysaccharide substance MPS-80 is prepared.
Get 500mg. Example Crude material obtained by alcohol precipitation of the culture solution obtained in the production example (3% MPS-80)
containing) in commercially available rat and mouse breeding feed.
10% was added and mixed. This is used as feed. As a control, 10% whey protein was added and mixed into the same commercially available rat and mouse breeding feed. This is used as feed. The protein content, energy content, etc. of the feed for each group was made to be the same. The animals used were spontaneously hypertensive male rats (SHR) weighing 40 to 50 g immediately after weaning. In the experimental area, 30 SHRs were raised on feed. In the experimental area, 30 SHRs were also raised on feed. In both experimental groups, 10 animals were sacrificed by exsanguination every 3 weeks, and the livers were removed. Lipid content in the liver was measured. The experimental results are shown in Table 1, Figures 5 and 6.
Shown in the figure. There was no difference in weight gain between the two experimental groups.
The total lipid content in the liver was significantly lower at 6 to 9 weeks of age in the experimental group. There were no differences in GOT and GPT between the two groups. Therefore, it can be seen that the accumulation of lipids in the liver was suppressed in rats fed the diet containing the high-molecular polysaccharide substance MPS-80. 【table】
第１図は高分子多糖類物質MPS−80の限外
過による展開図である。
ａ……高分子多糖類物質MPS−80、ｂ……
Blue Dextran。
第２図は高分子多糖類物質MPS−80の紫外部
吸収スペクトルを、第３図は同じく赤外部吸収ス
ペクトルを、第４図は同じくC13−NMRスペク
トルを示す図である。第５図は実施例における
SHRの肝臓中の総脂質量の変化を示す図、第６
図は同じく肝臓１ｇ中の脂質量の変化を示す図で
ある。
Ａ……実験区、Ｂ……実験区。
FIG. 1 is a development diagram of the polymeric polysaccharide substance MPS-80 obtained by ultrafiltration. a...High molecular polysaccharide substance MPS-80, b...
Blue Dextran. FIG. 2 shows an ultraviolet absorption spectrum of the polymeric polysaccharide substance MPS-80, FIG. 3 shows an infrared absorption spectrum, and FIG. 4 shows a C 13 -NMR spectrum. Figure 5 shows the example
Figure 6 showing changes in total lipid content in the liver of SHR.
The figure also shows changes in the amount of lipids in 1 g of liver. A... Experimental area, B... Experimental area.
Claims (1)
る脂肪肝抑制剤。1. A fatty liver inhibitor containing the high-molecular polysaccharide substance MPS-80 as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58100315A JPS59225120A (en) | 1983-06-07 | 1983-06-07 | Inhibitor against formation of jecur adiposum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58100315A JPS59225120A (en) | 1983-06-07 | 1983-06-07 | Inhibitor against formation of jecur adiposum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59225120A JPS59225120A (en) | 1984-12-18 |
| JPH0532371B2 true JPH0532371B2 (en) | 1993-05-14 |
Family
ID=14270743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58100315A Granted JPS59225120A (en) | 1983-06-07 | 1983-06-07 | Inhibitor against formation of jecur adiposum |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59225120A (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2764267B2 (en) * | 1988-04-20 | 1998-06-11 | 雪印乳業株式会社 | Functional food and drink with bile acid secretion promoting action |
| JP5247012B2 (en) * | 2006-07-25 | 2013-07-24 | 雪印メグミルク株式会社 | Fatty liver suppressant |
| US8821853B2 (en) | 2006-07-25 | 2014-09-02 | Megmilk Snow Brand Co., Ltd. | Anti-fatty liver agent |
| CN101983065B (en) * | 2008-03-07 | 2013-08-07 | 雪印惠乳业株式会社 | Agents for promoting secretion and/or suppressing decrease of adiponectin |
| JP5804542B2 (en) * | 2010-03-25 | 2015-11-04 | 雪印メグミルク株式会社 | Fatty liver prevention and / or inhibitor |
| EP2668851B1 (en) | 2012-05-29 | 2016-03-23 | Ueno Fine Chemicals Industry, Ltd. | Liver function-improving agent |
-
1983
- 1983-06-07 JP JP58100315A patent/JPS59225120A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59225120A (en) | 1984-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0728694B2 (en) | Food composition having intestinal regulating action | |
| Auricchio et al. | Isomaltose intolerance causing decreased ability to utilize dietary starch | |
| JPS6216638B2 (en) | ||
| US5939309A (en) | Bifidobacterium bifidum proliferation promoting composition containing xylooligosaccharide | |
| JPH0532371B2 (en) | ||
| JPH05246860A (en) | Preventive of large intestine cancer | |
| JP2928335B2 (en) | Antihypertensives and foods and beverages | |
| JP4054697B2 (en) | Constipation improving agent | |
| JPH10130160A (en) | Lipid metabolism improver and food containing the same | |
| HU191697B (en) | Process for preparing a new polysaccharide decreasing triglyceride blood level and pharmaceutical compositions containing thereof | |
| JPS6133840B2 (en) | ||
| KR100302505B1 (en) | Fermented product using lactic acid bacteria and cosmetic composition | |
| JPS6316118B2 (en) | ||
| JPH058173B2 (en) | ||
| JP2855283B2 (en) | Anti-ulcer agent and method for producing the same | |
| Sloven et al. | Hydrolysis and absorption of glucose polymers from rice compared with corn in chronic diarrhea of infancy | |
| JPH0859492A (en) | Antidiabetic drug | |
| JPH0899888A (en) | Glutathione peroxidase activator | |
| JPH06116156A (en) | Hypoglycemic agent | |
| JPS601877B2 (en) | Polymeric polysaccharide substance MPS-80 and its manufacturing method | |
| CN114391648B (en) | Preparation method of probiotic fermented oat composition with blood sugar and blood lipid reducing effects | |
| JPH09132533A (en) | Suppressant for both ulcer and hepatopathy comprising lactic acid bacterium fermentation product | |
| JP2003012538A (en) | Antioxidant agent | |
| JPH07330806A (en) | Neutral polysaccharide and its use | |
| JPS601878B2 (en) | antitumor agent |